Difference between revisions of "Midkine"
| Line 43: | Line 43: | ||
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| − | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/ | + | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1mkn.pdf ASAView] pdf |
| + | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1mkn.txt ASAView] txt | ||
| + | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1mkc.pdf ASAView] pdf | ||
| + | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1mkc.txt ASAView] txt | ||
|- | |- | ||
| Disorder prediction | | Disorder prediction | ||
Revision as of 08:27, 25 July 2007
| Template:Infobox header| Midkine | |
|---|---|
| Midkine | |
| Substrate peptide name | Midkine |
| Synonyms | Neurite outgrowth-promoting protein
Midgestation and kidney protein Amphiregulin-associated protein |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Extracellular, plasma |
| Swissprot ID | P21741 |
| Reactive glutamines | Q42, Q44, Q95 |
| Reactive lysines | K63 |
| Substrate sequence | GTCGAQTQRIRCR
NAQCQETIRV FGADCKYKFEN |
| Structure | 1MKN |
| Surface accessibility | ASAView pdf |
| Disorder prediction | IUPred |
| Reference | PMID:9083079 |
| Notes | It seems that Q42 and Q44 serve alternatively as glutamine donor substrates
It has enhanced activity upon crosslinking by TG2. |
| Template:Infobox header | | |
